...
首页> 外文期刊>Circulation: An Official Journal of the American Heart Association >Saphenous Vein Grafts With Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial.
【24h】

Saphenous Vein Grafts With Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes From the Project of Ex-Vivo Vein Graft Engineering via Transfection (PREVENT) IV Trial.

机译:进行冠状动脉搭桥手术的患者中具有多个与单个远侧目标的隐静脉移植物:通过转染的前静脉移植物工程(PREVENT)IV试验的一年移植物失败和五年结果。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background- Limited information exists on the intermediate-term graft patency and 5-year clinical outcomes of patients receiving saphenous vein grafts with multiple (m-SVG) versus single distal targets (s-SVG) during coronary artery bypass graft (CABG) surgery in the current era. Methods and Results- We studied the association of the use of m-SVG versus s-SVG conduits with 1-year SVG failure (defined as >/=75% angiographic stenosis) and 5-year clinical events (death; death or myocardial infarction [MI]; and death, MI, or revascularization) in 3014 patients undergoing their first CABG surgery enrolled in the Project of Ex-vivo Vein Graft Engineering via Transfection (PREVENT) IV. Of 3014 patients enrolled in PREVENT IV, 1045 (34.7%) had >/=1 m-SVGs during CABG. Vein graft failure at 1-year was higher for m-SVG compared with s-SVG (adjusted odds ratio 1.24, 95% confidence interval 1.03 to 1.48). At 5 years, the adjusted composite of death, MI (including perioperative MI), or revascularization (hazard ratio 1.15, 95% confidence interval 1.00 to 1.31) and death or MI (hazard ratio 1.21, 95% confidence interval 1.03 to 1.43) were significantly higher in patients receiving m-SVGs. Conclusions- In patients undergoing first CABG surgery, the use of m-SVG was associated with a higher 1-year vein graft failure rate and trends toward worse clinical outcomes. Additional studies are needed to better understand the most appropriate conduit to improve long-term graft patency and clinical outcomes of patients undergoing CABG surgery. In the meantime, these data should encourage the use of s-SVG over m-SVG when feasible.
机译:背景-在进行冠状动脉旁路移植术(CABG)的过程中接受多(m-SVG)相对于单个远端靶点(s-SVG)的大隐静脉移植的患者的中期移植物通畅性和5年临床结果的信息有限。当前时代。方法和结果-我们研究了使用m-SVG和s-SVG导管与1年SVG衰竭(定义为> / = 75%血管造影狭窄)和5年临床事件(死亡,死亡或心肌梗塞)的相关性[MI];以及死亡,MI或血运重建术)的3014例首次接受CABG手术的患者通过转染(PREVENT)IV参加了体外静脉移植工程。在参加PREVENT IV的3014名患者中,有1045名(34.7%)在CABG期间具有> / = 1的m-SVG。与s-SVG相比,m-SVG在1年时的静脉移植失败率更高(调整后的优势比1.24,95%置信区间1.03至1.48)。在5年时,调整后的死亡,心梗(包括围手术期心梗)或血运重建(危险比1.15,95%置信区间1.00至1.31)和死亡或心梗(危险比1.21,95%置信区间1.03至1.43)的组合接受m-SVGs的患者明显更高。结论-在首次进行CABG手术的患者中,m-SVG的使用与较高的1年静脉移植失败率和临床预后恶化趋势相关。需要进行其他研究以更好地了解最合适的导管,以改善接受CABG手术的患者的长期移植物通畅性和临床结局。同时,在可行时,这些数据应鼓励使用s-SVG而非m-SVG。

著录项

相似文献

  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号